SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS
Sellas Life Sciences Group (SLS) shares rose 18% to a 4-year high as its Phase 3 Regal trial of galinpepimut-S (GPS) in AML nears the final analysis stage. CEO Angelos Stergiou said survival appears longer than expected; the study had 78 events as of May 11, with two remaining. Success target: median OS 12.6 months vs 8.1 months.
How this was made
The 30-second read
Why it matters
Investors are trading the probability-weighted path to topline data as the trial approaches the 80-event threshold, with CEO commentary suggesting survival is stronger than expected and outlining a potential pre-BLA meeting after topline.
Market read
A late-stage biotech timing update plus CEO survival commentary can materially shift near-term expectations for topline timing and regulatory next steps, supporting momentum trading.
What to watch
The article does not provide new safety, event timing certainty, or updated guidance for SLS009, so upside may be driven more by narrative than measurable endpoints.
Background
Sellas Life Sciences is evaluating galinpepimut-S (GPS) in AML patients in second remission after salvage therapy in the Phase 3 REGAL study.
Ticker impact
Sellas shares jumped 18% as CEO said REGAL Phase 3 is near final event, with survival “unexpectedly long” and potential FDA pre-BLA talks.
Bullish bias for continued momentum into the final-event milestone, but volatility risk remains high given blinded status and only two events remaining.
The article provides a fresh, time-sensitive update (78 events as of May 11, only two remaining) plus a new CEO quote about survival appearing longer, which can drive speculative positioning ahead of topline.
Market effects
Reinforces sentiment for AML immunotherapy and WT1-targeting platforms, potentially lifting peer attention to late-stage readouts.
Primarily US small-cap biotech sentiment, with limited direct regional spillover.
Modest global relevance, as the catalyst is company-specific clinical trial timing and FDA interaction planning.
Counterpoint
Blinded trial status means survival commentary is not confirmed by unblinded data, so the stock can retrace if topline later disappoints.
Key entities
- companySellas Life Sciences Group
Subject of the article; GPS REGAL Phase 3 is near the final event threshold and CEO discussed potential FDA talks.
- product_candidateGPS (galinpepimut-S)
Lead therapy in REGAL; CEO suggested survival appears unexpectedly long and discussed broader WT1 indication potential.
- clinical_trialREGAL Phase 3 study
AML trial in second remission; article cites 78 events as of May 11 and only two events remaining before topline threshold.
- product_candidateSLS009
Second AML candidate in Phase 2; article references prior data and expectations for topline later this year.
